A5057469474- Ovarian cancer diagnosis and treatment
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Endometrial and Cervical Cancer Treatments
- Gastrointestinal Tumor Research and Treatment
- Cervical Cancer and HPV Research
- Testicular diseases and treatments
- Lung Cancer Research Studies
- Gynecological conditions and treatments
- Cancer Genomics and Diagnostics
- Colorectal and Anal Carcinomas
- Lymphoma Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Cancer Immunotherapy and Biomarkers
- Sexual Differentiation and Disorders
- Fibroblast Growth Factor Research
- MicroRNA in disease regulation
- Education and Social Development in Ukraine
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Galectins and Cancer Biology
- HER2/EGFR in Cancer Research
- Angiogenesis and VEGF in Cancer
Royal Marsden Hospital
2023-2025
Edward Via College of Osteopathic Medicine
2024
Royal Marsden NHS Foundation Trust
2022-2023
Emory University
2016-2021
The Ohio State University
2014
Renown Regional Medical Center
2010
Ealing Hospital NHS Trust
2006
Ealing Hospital
2006
Northern Indiana Cancer Research Consortium
2005
Walt Disney (United States)
2005
PURPOSE Topotecan and paclitaxel were evaluated in a randomized, multicenter study of patients with advanced epithelial ovarian carcinoma who had progressed during or after one platinum-based regimen. PATIENTS AND METHODS Patients received either topotecan (1.5 mg/m2) as 30-minute infusion daily for 5 days every 21 (n = 112) (175 infused over 3 hours 114). bidimensionally measurable disease assessed efficacy toxicity. RESULTS Response rate was 23 112 (20.5%) topotecan-treated 15 114 (13.2%)...
PURPOSE Topotecan, a topoisomerase I inhibitor, was evaluated in multicenter, phase II study of women with epithelial ovarian carcinoma who relapsed after one or two prior regimens that included platinum and paclitaxel. PATIENTS AND METHODS Topotecan 1.5 mg/m2 daily administered as 30-minute infusion for 5 consecutive days on 21-day cycle. Eligibility criteria bidimensionally measurable disease, Eastern Cooperative Oncology Group performance status 2 less, adequate bone marrow, liver, renal...
The aim of this single-arm, phase II study was to estimate the tumor response rate and safety profile erlotinib HCl (erlotinib, Tarceva, OSI-774) monotherapy in patients with refractory, recurrent, HER1/EGFR-positive epithelial ovarian tumors, who had failed prior taxane and/or platinum-based chemotherapy. Thirty-four received 150 mg orally once daily for up 48 weeks or until disease progression dose-limiting toxicity. Two partial responses, lasting 8+ 17 weeks, giving an objective 6% (95%...
PLATFORM is an adaptive phase II study assessing maintenance therapies in advanced esophagogastric adenocarcinoma (OGA). We evaluated the role of capecitabine plus a vascular endothelial growth factor receptor 2 inhibitor ramucirumab (cape-ram) these patients. Human epidermal (HER2)-negative patients with OGA stable or responding disease after 18 weeks induction platinum-based chemotherapy were randomly assigned 1:1 to surveillance cape-ram. The primary end point was progression-free...
3521 Background: People living with HIV (PLHIV) usually have more advanced cancer at diagnosis and a higher cancer-related mortality, posing significant burden on health care. However, clinical studies often exclude patients HIV, thereby limiting access to therapies for this patient population. PLHIV 25- 35-fold chance of being diagnosed SCAC than individuals who are negative. We therefore evaluated safety efficacy retifanlimab in SCAC. Methods: The study designs POD1UM-202 (NCT03597295)...
446 Background: ICONIC evaluated 4+4 cycles of FLOT-A (2-weekly standard FLOT with 10mg/kg the anti-PDL1 antibody avelumab) for perioperative treatment early-stage OGA. We report R0 resection rates, pathologic complete response rates (pCR), tumour regression grades (TRG) according to Mandard classification and progression free survival (PFS) data in modified intention treat population (mITT), translational analyses. Methods: is a single-arm phase II trial patients (pts) ≥cT2-4 or N+ The pCR...
To determine the maximum-tolerable dose (MTD) of paclitaxel in a phase I dose-escalation study when combined with cisplatin patients advanced ovarian cancer receiving filgrastim for prophylaxis myelosuppression.A total 23 stage II (bulky residual), III, or IV epithelial were treated (following debulking surgery) as 3-hour infusion followed by (75 mg/m2) administered over 4 hours on day 1, repeated every 21 days six cycles. Filgrastim (5 micrograms/kg/d) was subcutaneously (SC) beginning 2...
The sonographic appearance of 67 ovaries in 34 postmenopausal women who underwent preoperative transvaginal sonography (TVS) was correlated to findings on pathologic examination. Both were detected by TVS 60% the examined; 85%, at least one ovary detected. size normal, sonographically visualized 2.2 +/- 0.7 cm transverse, 1.2 0.3 anteroposterior, and 1.1 0.6 longitudinal axes, with an average volume 2.6 2.0 cm3. that not x 0.4 (range, 1.3 cm); most these (five six) atrophic exam. difference...
The aim of this single-arm, phase II study was to estimate the tumor response rate and safety profile erlotinib HCl (erlotinib, Tarceva™, OSI-774) monotherapy in patients with refractory, recurrent, HER1/EGFR-positive epithelial ovarian tumors, who had failed prior taxane and/or platinum-based chemotherapy. Thirty-four received 150 mg orally once daily for up 48 weeks or until disease progression dose-limiting toxicity. Two partial responses, lasting 8+ 17 weeks, giving an objective 6% (95%...
Abstract Background: The utility of molecular residual disease (MRD) detection by circulating tumor (ct)DNA in early-stage (pT2+ or N+, M0) esophagogastric adenocarcinoma treated with peri-operative systemic therapy has not been assessed prospective trials. Methods: This exploratory analysis the phase 2 ICONIC trial (NCT03399071), whether ctDNA can predict recurrence and determine efficacy 4xFLOT+avelumab (FLOT-A) before after surgery. Exome sequencing pre-treatment biopsies was successful...
This paper investigates the potential use of information systems (IS) for enhancing supply chains organisations positioned in intellectual property (IP) sector. Exploratory research has been conducted through lens a patent and trade mark agent who is involved advising on range IP issues. The highlights opportunities offered by IS (including online technologies) generally improving provision business services e.g. automating chain processes. More specifically, though, it have integrating...
5536 Background: Induction TC is a standard of care for advanced OC. GC approved use in recurrent platinum-sensitive Phase II trials show G + platinum to be active as first-line therapy Also, evidence suggests that 12-month T consolidation improves progression- free survival (PFS). This trial compared safety and efficacy induction regimens followed by elective consolidation. interim disclosure, permitted protocol, reports toxicity response results the first 449 pts randomized regimens....
5049 Background: AMG 386 is an investigational peptide-Fc fusion protein that inhibits angiogenesis by preventing angiopoietin 1/2 interaction with the Tie2 receptor. We report on ongoing, open-label study of combined PLD or T in advanced ovarian cancer. Methods: In part 1 this 2-part dose de-escalation study, adult patients (pts) recurrent, epithelial ovarian, fallopian tube, primary peritoneal cancer and GOG performance 0 1, ≤ 3 prior chemotherapy regimens received, IV, at 10 mg/kg QW plus...
LBA5008 Background: Safety and efficacy of GC or TC induction followed by elective T consolidation (Tcon) were evaluated. Methods: Patients (pts) with stage IC-IV epithelial OC randomized to GC: G 1,000 mg/m 2 on days 1, 8 plus C AUC=5 day 1; TC: 175 AUC=6 1 for a total six 21-day cycles. Pts complete response (CR) could receive Tcon 135 every 28 12 Non-CR pts received single-agent crossover (CO) therapy (CO-T CO-G 8) 21 until CR progression disease (PD). PD death in 636 was required compare...